InnovAge vs LifeStance Health
INNV and LFST side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INNV and LFST compare
LifeStance Health is the larger company, worth 4.2 times as much as InnovAge ($5.5B against $1.3B).
LifeStance Health grew revenue faster over the last twelve months (22.6% versus 15.9% for InnovAge).
LifeStance Health keeps more of each dollar of sales as profit, with a net margin of 4.3% compared with −0.26% at InnovAge.
LifeStance Health scores higher on the StockData Score (12 against 10 for InnovAge), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INNV | LFST |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $5.5B |
| Share price | $9.50 | $14.37 |
| Change, 1 year | 88.1% | 123% |
| Change, 5 years | 13.0% | 66.1% |
| Beta (5Y) | 0.68 | 1.18 |
| Employees | 2,500 | 11K |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 2 | 3 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 75.6× |
| P/S | 1.3× (better) | 3.3× |
| P/B | 5.5× | 3.7× (better) |
| EV/EBITDA | 50.8× | 37.4× (better) |
| P/FCF | 25.7× (better) | 30.6× |
| FCF yield | 3.9% (better) | 3.3% |
| Fair value | $5.78 | $5.90 |
| Margin of safety | −64.3% (better) | −143% |
| Growth | ||
| Revenue growth (TTM) | 15.9% | 22.6% (better) |
| Revenue growth, 5Y average | 9.2% | – |
| Profitability | ||
| Gross margin | 23.0% | – |
| Operating margin | 0.26% | 6.2% (better) |
| Net margin | −0.26% | 4.3% (better) |
| FCF margin | 5.1% | 10.7% (better) |
| Return on equity | −1.1% | 4.8% (better) |
| Return on invested capital | 1.2% | 5.4% (better) |
| Financial health | ||
| Debt / equity | 0.20 | 0.18 (better) |
| Net debt / EBITDA | −3.93 | 0.35 (better) |
| Interest coverage | – | 10.6× |
| Current ratio | 1.05 | 1.44 (better) |
| Altman Z-score | 4.24 | 5.26 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 13.5% | 98.7% |
| Held by insiders | – | 64.7% |
| Insider net buying, 12 months | −$227M (better) | −$847M |
| Short interest, % of float | – | 10.1% |
Go deeper
- INNV stock overview
- INNV income statement
- INNV valuation and score
- LFST stock overview
- LFST income statement
- LFST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.